Privacy Overview
This website uses cookies to improve your experience while you navigate through the website. Out of these, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may affect your browsing experience.
Always Active
Necessary cookies are absolutely essential for the website to function properly. These cookies ensure basic functionalities and security features of the website, anonymously.
Functional cookies help to perform certain functionalities like sharing the content of the website on social media platforms, collect feedbacks, and other third-party features.

No cookies to display.

Performance cookies are used to understand and analyze the key performance indexes of the website which helps in delivering a better user experience for the visitors.

No cookies to display.

Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics the number of visitors, bounce rate, traffic source, etc.
Advertisement cookies are used to provide visitors with relevant ads and marketing campaigns. These cookies track visitors across websites and collect information to provide customized ads.
Other uncategorized cookies are those that are being analyzed and have not been classified into a category as yet.

Estimated undertreatment of carbapenem-resistant Gram-negative bacterial infections in eight low-income and middle-income countries: a modelling study

Over the past quarter century, antimicrobial resistance (AMR) has emerged as a major global health threat. It is estimated that almost 1·1 million deaths annually are a direct result of AMR—more than the combined deaths from HIV/AIDS and malaria in 2022.1–3 Overwhelmingly, low-income and middle-income countries (LMICs) bear this burden—nearly 90% of AMR-related deaths each year are estimated to occur in LMICs. Today, a child born in Africa is 58 times more likely to die from a drug-resistant infection in the first 5 years of life than one born in a high-income country. With bacterial drug resistance rates continuing to increase, and without concerted action, almost 40 million cumulative deaths are projected by 2050.

 

Authors: 

Anant Mishra, Rahul Dwivedi, Kim Faure, Prof Daniel J Morgan, Jennifer Cohn

 

Read the study